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Abstract
Objective:The aim of the current studywas to investigate the long-term cognitive effects of electroconvulsive therapy (ECT)
in a sample of adolescent patients in whom schizophrenia spectrum disorders were diagnosed.
Methods: The sample was composed of nine adolescent subjects in whom schizophrenia or schizoaffective disorder was
diagnosed according to DSM-IV-TR criteria on whom ECT was conducted (ECT group) and nine adolescent subjects
matched by age, socioeconomic status, and diagnostic and Positive and Negative Syndrome Scale (PANSS) total score at
baseline on whom ECT was not conducted (NECT group). Clinical and neuropsychological assessments were carried out at
baseline before ECT treatment and at 2-year follow-up.
Results: Significant differences were found between groups in the number of unsuccessful medication trials. No statistically
significant differenceswere found between the ECTgroup and theNECTgroup in either severity as assessed by the PANSS, or in
any cognitive variables at baseline. At follow-up, both groups showed significant improvement in clinical variables (subscales of
positive, general, and total scores of PANSS and Clinical Global Impressions–Improvement). In the cognitive assessment at
follow-up, significant improvement was found in both groups in the semantic category of verbal fluency task and digits forward.
However, no significant differences were found between groups in any clinical or cognitive variable at follow-up. Repeated
measures analysis found no significant interaction of time· group in any clinical or neuropsychological measures.
Conclusions: The current study showed no significant differences in change over time in clinical or neuropsychological
variables between the ECT group and theNECT group at 2-year follow-up. Thus, ECT did not show any negative influence on
long-term neuropsychological variables in our sample.
Introduction
Electroconvulsive therapy (ECT) has been demonstratedto be a safe and effective procedure in adult patients. There is
also evidence that ECT is useful in children and adolescents with
certain severe psychiatric disorders who fail to respond to phar-
macotherapy or require a quick response due to life-threatening
symptoms (Ghaziuddin et al. 1996;Moise and Petrides 1996; Baeza
et al. 2010). Variable rates of improvement or remission of
symptoms by the end of the course of ECT have been observed:
63% for patients with depression, 80% in patients with mania, and
42% for those with schizophrenia (Rey and Walter 1997). A rela-
tively low incidence of relevant adverse events in adolescents has
also been described (Taieb et al. 2002; Bloch et al. 2008).
In adults, short-term follow-up studies have shown memory
impairments in patients treated with ECT (for a review, see Rami-
Gonzalez et al. 2001; Ingram et al. 2008). Specifically, studies with
patients with different mood disorders have found difficulties en-
coding new information and in long delay verbal recall after ECT
treatment (Steif et al. 1986; Rami-Gonzalez et al. 2003b) as well as
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retrograde amnesia for remote events (Squire 1977; Lisanby et al.
2000; Ingram et al. 2008). Moreover, electrode position, energy,
and type of current have been related with the degree of cognitive
impairments. Specifically, some of them (Weeks et al. 1980; Squire
and Chace 1996; Sackeim et al. 2008) have found that unilateral
right positions have less severe cognitive effects than bilateral
positions, which support previous review studies (Squire 1977;
Calev et al. 1995; Squire and Chace 1996). Sackeim et al. (2008) in
a double-blind study investigate the effects of different electrode
placement (bilateral vs. right unilateral) and pulse width (0.3 vs.
1.5ms) and found that the ultrabrief right unilateral group had less
cognitive side effects than the other groups. Regarding electrical
dosage, Sackeim et al. (2000) compared different electrode position
(bilateral vs. right unilateral) and electric dosage (50% vs. 150%
and 500% above the seizure threshold) and found that a high dosage
result in a greater cognitive impairment. Most of these studies have
also shown that both learning and retaining were totally recovered
between a few weeks and 7 months after the ECT series (Weeks
et al. 1980; Frith et al. 1983; Calev et al. 1991; Squire and Chace
1996). Moreover, Zervas et al. (1993) associated patient age in
adults to the risk of short-term memory deficits in patients treated
with ECT. Thus, the authors found more severe deficits in older
patients for verbal and visuospatial anterograde and retrograde
memory, thereby concluding that older patients were more vul-
nerable to cognitive effects of ECT.
A few studies have investigated other cognitive functions, most
finding no differences between ECT and no-ECT groups of patients
(Vothknecht et al. 2003; Rami et al. 2004). However, two case-
control studies analyzing the effects of maintenance ECT found
some impairments in verbal fluency (Rami-Gonzalez et al. 2003a)
and speed of information processing (Tsourtos et al. 2007).
In adolescents, Ghaziuddin et al. (2000) reported a sample of 16
adolescents with mood disorder and administered a cognitive bat-
tery before the ECT treatment, 1 week after the last ECT session,
and *8 months after the last session. Results showed significant
impairments in attention, verbal and visual delayed recall, and
verbal fluency between the pretreatment evaluation and 1 week
post-treatment assessment, which had disappeared at the second
post-treatment assessment 8 months later.
Regarding long-term studies with a follow-up longer than 1 year,
there are to our knowledge only three studies that have analyzed the
cognitive effects of ECT in adult samples (Russell et al. 2003;
Johanson et al. 2005; MacQueen et al. 2007). Johanson et al. (2005)
analyzed the cognitive effects of ECT in 55 patients with depression
whowere followed up 20–24 years after the ECT treatment. Patients
showed a slight impairment of working memory and verbal mem-
ory, but there was no control group against which to make a com-
parison. MacQueen et al. (2007) studied subjective and objective
memory impairments in three samples of subjects matched for age
and sex but not for clinical severity: A group of 20 patients with
bipolar disorder treated with ECT, a group of 20 patients with bi-
polar disorder with no ECT treatment, and 20 healthy controls were
followed up during 45 months. The authors concluded that the pa-
tients who received ECT had significantly lower scores in memory
and verbal learning tests. Nevertheless, Russell et al. (2003) carried
out a retrospective study of 43 patients with different diagnoses
(depression, bipolar disorder, and schizoaffective disorder) who had
received at least 1 year of maintenance ECT and found no signifi-
cant differences in cognitive domains assessed with the Mini-
Mental State Exam between baseline and follow-up evaluations.
Only one study has analyzed cognitive effects of ECT in a
sample of adolescents with a long-term follow-up (Cohen et al.
2000). A sample of 10 adolescents in whom mood disorder was
diagnosed were followed up until 3.5 years after the last ECT
session and compared with 10 psychiatric comparison subjects. The
authors found that adolescents treated with ECT did not show
cognitive impairment at long-term follow-up in objective measures
of cognitive function; nevertheless, they found a subjective mem-
ory impairment measured with the Squire’s Subjective Memory
Questionnaire in two subjects.
No follow-up studies have been carried out in relation to cog-
nition in adolescents with schizophrenia spectrum disorder treated
with ECT.
Thus, taking into account this lack of information from previous
long-term studies in children and adolescents with schizophrenia
spectrum disorder, the aim of the current study was to investigate
the long-term cognitive effects of ECT in a sample of adolescent
patients with these disorders. We hypothesized that no significant
differences would be found in cognitive measures after 2-year
follow-up between an ECT group and a no-ECT group.
Methods
Subjects
We included nine adolescent subjects aged between 13 and 18
(22% men), and in whom schizophrenia (n= 7) or schizoaffective
disorder (n= 2) was diagnosed according to DSM-IV-TR criteria
on whom ECT was conducted following the American Psychiatric
Association (2001) and the American Academy of Child and
Adolescent Psychiatry (AACAP) recommendation criteria (ECT
group) (Ghaziuddin et al. 2004). All subjects were admitted between
January 2005 and December 2009 into the inpatient ward of the
Child and Adolescent Psychiatry and Psychology Department of
Hospital Clinic of Barcelona. Of the 137 patients with schizophrenia
spectrum disorder (schizophrenia or schizoaffective disorder, DSM-
IV criteria) hospitalized in our center during this period, 13 of them
(9.49%) were treated with ECT. Our ECT Committee approved the
indication for each of the patients, and written informed consent for
ECT was provided by the patients’ parents or legal guardians. Lack
of response to at least two adequate pharmacotherapeutic trials and/
or intolerance to medication side effects were the most common
reason for indication of ECT (n= 7; 77.8%). ECT was considered
earlier in other cases when subjects presented with catatonia (n= 2;
22.2%). Statistical analysis was performed with a sample of nine
subjects who had completed all clinical and neuropsychological
assessments. All subjects received additional pharmacotherapy
(including antipsychotics, mood stabilizers, antidepressants, and
benzodiazepines) during the acute ECT phase. No negativism, no
mutism, and no staring were observed in any of the patients with
catatonia when neuropsychological tests were assessed.
Subjects treated with ECT were compared with nine subjects
selected from the same 137 treated during this period (44% men).
Schizophrenia (n = 7) or schizoaffective disorder (n= 2) was diag-
nosed in these controls, and they were treated with psychiatric
drugs but without ECT (NECT group). They were matched for age,
socioeconomic status, and PANSS at baseline. Socioeconomic
status of the sample was estimated with the Hollingshead Redlich
scale (Hollingshead and Redlich 1958).
Exclusion criteria for both groups included (1) presence of an-
other concomitant Axis I disorder at the time of assessment that
might account for the psychotic symptoms, including substance-
induced psychotic disorder, post-traumatic stress disorder, or acute
stress disorder; (2) Intelligence Quotient (IQ) below 70 with im-
paired functioning; (3) pervasive developmental disorder; and (4)
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neurological disorders, including history of head trauma with loss
of consciousness.
All patients were retrospectively assessed at baseline and at 2-
year follow-up; and the study was approved by the Ethics Com-
mittee of the institution.
Psychopathological assessment
All subjects were evaluated with the Positive and Negative
Syndrome Scale (PANSS) and the Clinical Global Impressions–
Improvement (CGI-I) Scale just before beginning the ECT course
and at the 2-year follow-up assessment.
PANSS: This is a 30-item rating scale that aims at assessing the
symptom severity of subjects with psychosis. It is subdivided into
three subscales—positive, negative, and general psychopathology—
and a total score (Kay et al. 1987; Peralta and Cuesta 1994). Each
subscale and the total score are all evaluated from 1 to 7 according to
the severity of the symptoms. It was always administered by the same
psychiatrist (I.B.).
CGI-I scale: This is a clinical scale scored from 1 to 7 that
assesses the severity of symptoms. A better level is indicated by
lower scores (Guy 1976).
The Neurological Examination Scale (NES) (Buchanan and
Heinrichs 1989): This scale assesses neurological soft signs. It
comprises 26 items clustered into four subscales: Sensory integra-
tion, motor coordination, sequencing of complex motor tasks, and
other neurological soft signs. In this study, it was used to assess
motor and coordination problems that could affect subjects’ perfor-
mance in neuropsychological tests.
Therapeutic intervention
All subjects received ECT thrice per week with a constant-
current, brief-pulse device. Using a systematic protocol, all treat-
ment stimuli were delivered with bifrontotemporal electrode
placement administered using a MECTA-SR2 ECT device. Seizure
threshold was titrated at the first session, with Stimulus dosing at
subsequent treatments of 1.5 times the seizure threshold. Table 1
shows the ECT parameters.
Electroencephalographic and motor seizure manifestations were
monitored to ensure adequate duration. Succinylcholine (30–
120mg), atropine (0–1mg), and sodium tiopenthal (75–450mg) or
propophol (120–170mg) were used for anesthesia. The acute ECT
course was continued until the acute symptoms remitted or no
further improvement was shown over the course of three consec-
utive sessions.
Neuropsychological assessment
Cognitive assessment was performed between 4 and 8 weeks
after admission when subjects had reached a low in acute psychotic
symptoms, before the ECT treatment and at 2-year follow-up, by
means of a comprehensive neuropsychological battery designed to
assess the following cognitive domains: IQ, working memory, at-
tention, verbal learning and memory, and executive functioning.
To rule out mental retardation, IQ was estimated using the Block
Design and Vocabulary subtests of the Wechsler Adult Intelligence
Scale-III Revised (WAIS III) (Wechsler 2001) or the Wechsler In-
telligence Scale for Children-Revised (Wechsler 1974), depending on
the subject’s age. Raw scores for each subscale were converted into
standard scores with a mean of 10 and a standard deviation of 3.
Working memory was evaluated using the scores obtained on
Digits backward and Letter-Number Sequencing of the WAIS III
(Wechsler 2001). The first task requires the subject to say in reverse
order the digits that have been read by the examiner. In the letter-
number sequencing task, the examiner reads a list of letters and
numbers and asks the subject first to say the numbers, from lowest
to highest, and then the letters, in alphabetical order.
Attention was assessed by means of the Trail Making Test part A
(TMT-A) (Reitan and Wolfson 1985) and Digits forward of the
WAIS III (Wechsler 2001). In the first task, the subject is instructed
to join with lines the numbers from 1 to 25 on a sheet of paper in the
shortest time possible. The time of response was taken into account.
In Digits forward, the subject should repeat a series of numbers in
the same order as has been read by the examiner.
Verbal memory and learning were evaluated by the Verbal
Learning Test-Complutense Spain, the Spanish adaptation of the
California Verbal Learning Test, which provides a learning curve
and an immediate and delayed memory score (Benedet and Ale-
jandre 1998).
Finally, executive functions were assessed by number of cate-
gories, number of mistakes, number of perseverative errors, and
number of perseverations on the Wisconsin Card Sorting Test
(WCST) (Heaton et al. 1997), the interference part of the Stroop test
(Golden 1978), the TMT part B (TMT-B) (Reitan and Wolfson
1985), and the verbal fluency task (FAS) (Lezak 1995). The WCST
is a measure of executive function that requires planning strategies
and cognitive flexibility to change the use of learned strategies. The
interference part of the Stroop test measures the subject’s ability to
inhibit an automatic predominant response. The FAS is a test of
verbal fluency that requires the subjects to generate as many words
as possible beginning with a given letter in 60 seconds. In the TMT-
B, subjects have to join with lines, alternatively, numbers (in in-
creasing order) and letters (in alphabetical order) in the shortest
possible time. We used the time to complete the task as a measure
of executive function.
Statistical analysis
To test the normality of the sample distribution, the Kolmo-
gorov-Smirnov test was applied, with the Levene test to assess the
Table 1. Electroconvulsive Therapy Parameters
Mean Maximum Minimum Median Standard deviation Valid N sessions
Pulse width (ms) 1 2 1 1 0 120
Frequency (hertz) 65 80 60 60 8 120
Stimulus duration (s) 0.89 1.50 0.75 1.00 0.15 120
Current (amps) 0.63 0.80 0.60 0.60 0.07 120
Number ECT sessions 13 20 7 12 4
ECT= electroconvulsive therapy.
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equality of variances. These two conditions were achieved for both
clinical and neuropsychological variables. Categorical socio-
demographic variables were compared between the two groups
using the chi-square test or t-test as appropriate. Between-group
comparisons were conducted at first assessment and at 2-year
follow-up via multivariate analysis of variance (MANOVA) with
variables that differed between groups as covariates. Bonferroni
correction for multiple comparisons was applied to avoid the
presence of false positives. To assess the change between the first
and the second assessment in clinical and neuropsychological
variables, a repeated-measures analysis for the General Linear
Model was conducted. In neuropsychological assessment, both
analyses were conducted according to distinct cognitive domains
(Table 2 shows cognitive domains and the associated neu-
ropsychological variables). All analyses were performed using the
statistical package SPSS 15.0.
Results
Socio-demographic characteristics of the sample
Table 2 shows the gender, age, and socio-economic status of
ECT and NECT groups. No significant differences in age, sex, or
socio-economic status were found between these two groups.
Treatment characteristics of the sample
All subjects were receiving pharmacological treatment at first
assessment (Table 3). Significant differences were found between
groups in the number of unsuccessful medication trials (t = - 2.357,
p = 0.034) and dose (t = 2.089, p = 0.048), both being higher in the
ECT group than in the NECT group. Taking into account that the
number of failed treatments is interpreted as a severity index, sta-
tistical analysis was performed with this variable as a covariate.
The mean number of ECT sessions per patient was 12.67– 3.4
during the acute phase. The mean duration of EEG seizure was
45.8 – 17.2 (minimum = 21 s; maximum = 93 s). No subjects pre-
sented prolonged seizures.
With regard to adverse events with ECT, only mild and transient
side effects were reported during and after ECT sessions, such as
headache (5.9%) and agitation (0.5%). There were no cases of
tardive seizures.
At second assessment, two subjects in the ECT group and one
patient in the NECT group were not taking medication. All of them
reported that they did not want to be on pharmacological treatment.
Comparison between ECT group and no-ECT group
at first assessment
No statistically significant differences were found between the
ECT group and NECT group in global severity of symptomatology
at baseline (PANSS: F= 0.368, df = 4.13, p = 0.826; CGI: F = 1.276,
df = 1, p = 0.279), nor were significant differences observed in any
subscale of NES at baseline (sensory integration: F = 0.170,
p = 0.691; motor coordination: F= 0.040, p = 0.847; sequencing of
complex motor tasks: F = 0.061, p= 0.812; other neurological soft
signs: F= 1.200, p= 0.305). Table 2 shows the results obtained by
each group on PANSS and CGI.
Regarding the cognitive variables, no significant differences
were found between the groups at first assessment (Working
Memory: F = 1.507, df = 2.15, p = 0.261; Attention: F = 1.506,
df = 2.15, p= 0.261; Verbal Memory: F = 1.424, df = 3.14,
p = 0.288; Executive Functions: F = 1.948, df = 8.6, p = 0.316).
Table 2 shows the cognitive variables in both groups.
Comparison between ECT group and no-ECT group
regarding changes at 2-year follow-up
Regarding changes between the first and the second assessment,
both groups showed significant improvement in clinical variables,
specifically in the subscales of positive, general, and total score of
PANSS (F= 25.504, df = 4.13, p < 0.001) and CGI (F = 110.278,
df = 1, p < 0.001). Moreover, repeated-measures analysis found no
significant interaction of time · group in either PANSS (F = 1.185,
df = 4.13, p = 0.363) or CGI (F = 0.405, df = 1, p= 0.533), which
indicates that changes in clinical variables did not differ between
the groups (Table 4).
Overall, the analysis of cognitive variables showed higher scores
in some attentional (F= 12.753, df = 2.15, p = 0.001) and executive
function variables (F = 4.239, df = 8.6, p = 0.048). Specifically, in
our sample, there was an improvement in digits forward at second
assessment in both ECT and NECT groups and in the semantic
category of FAS. No significant changes were found in other
cognitive measures between the first and the second assessment
either in the ECT or in the NECT group (Working Memory:
F = 1.138, df = 2.15, p= 0.347; Verbal Memory: F = 1.531,
df = 4.12, p= 0.255). Table 4 shows changes in PANSS, CGI, and
neuropsychological variables in both groups. As in the case of
clinical variables, the repeated-measures analysis did not reveal
significant differences in the interaction time · group (Working
Memory: F = 0.063, df = 2.15, p= 0.939; Attention: F = 1.124,
df = 2.15, p= 0.351; Verbal Memory: F = 0.90, df = 4.12, p= 0.984;
Executive Functions: F = 2.216, df = 8.6, p= 0.174), which means
that there were no significant differences between the groups in
terms of changes in neuropsychological measures.
Comparison between ECT group and no-ECT group
at 2-year follow-up assessment
At 2-year follow-up, there were no significant differences be-
tween groups in any clinical variable (PANSS: F = 2.152, df = 3.14,
p = 0.152; CGI: F= 2.048, df = 1, p= 0.176), and no significant
differences were observed between the groups in any NES subscale
(sensory integration: F= 0.736, p = 0.416; motor coordination:
F = 0.143, p= 0.715; sequencing of complexmotor tasks: F= 0.581,
p = 0.468; other neurological soft signs: F = 3.540, p = 0.097).
The comparison of cognitive variables showed no significant
differences between ECT and NECT groups in any neuropsycho-
logical measure after Bonferroni adjustment (Working Memory:
F = 1.653, df = 2.15, p = 0.232; Attention: F= 2.107, df = 2.15,
p = 0.164; Verbal Memory: F= 0.202, df = 3.13, p= 0.892; Execu-
tive Functions: F= 2.355, df = 8.9, p= 0.156).
Table 2 shows clinical and neuropsychological results of both
groups at follow-up assessment.
Discussion
The main finding of the current study was that, as hypothesized,
after 2 years, neuropsychological changes in subjects treated with
ECT were similar to those found in subjects not treated with ECT.
We found no significant differences in any changes in clinical or
neuropsychological variables between the groups during follow-up
or at second assessment after 2 years.
Specifically, in our study, both the ECT and NECT groups were
matched by age and total PANSS score; therefore, subjects had
similar severity of clinical variables at baseline. As was expected,
the ECT and NECT groups differed in the number of unsuccessful
medication trials, this is due to the fact that the lack of response to at
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least two antipsychotics is a recommendation criteria of ECT in the
AACAP (Ghaziuddin et al. 2004). Regarding the cognitive vari-
ables, our study supports other investigations that have assessed the
influence of ECT on cognition and have reported no differences in
memory and learning after a few weeks to 7 months of treatment
(Weeks et al. 1980; Frith et al. 1983; Smith et al. 2010). Most of
these studies do not have a control group against which to compare
the baseline results (Calev et al. 1991; Squire and Chace 1996;
Smith et al. 2010), and none of them have matched both groups
while taking into account the psychopathology that has a clear
influence on neuropsychological performance (Basso et al. 1998;
Bilder et al. 2000; Fitzgerald et al. 2004; Good et al. 2004).
Matching by total PANSS score, our results did not reveal any
difference in cognitive variables at first assessment.
At follow-up, our study showed a significant improvement in
positive, general, and total score of PANSS in both groups. Previous
studies carried out with adolescent samples treated with antipsychotics
had showed an improvement in clinical severity of symptoms assessed
with the PANSS (Sikich et al. 2008; Arango et al. 2009; Haas et al.
2009; Robb et al. 2010). With ECT and in adolescent patients, Baeza
et al. (2010) analyzed a sample of 13 adolescents with schizophrenia
syndrome disorder followed-up during 6 months and observed a sig-
nificant improvement in positive and general PANSS subscales scores.
Moreover, Rey and Walter (1997) reviewed studies published about
the use of ECT in persons 18 years of age or younger, concluding that
the rate of improvement across the studies was 42% for schizophrenia
immediately after the ECT treatment and 10% 6 months after ECT.
Interestingly, in our study, the repeated-measures analysis found
no significant interaction of time · group; thus, changes in clinical
variables seemed to be similar in both groups and were independent
of the ECT treatment.
Regarding the cognitive assessment, an improvement in digits
forward and the semantic category of FAS was found in both
groups 2 years after the ECT treatment. Very few studies have
analyzed these cognitive functions. Rami-Gonzalez et al. (2003a)
found impairment in verbal fluency. However, the sample of that
study was composed of patients with different diagnoses (schizo-
phrenia, depression and bipolar disorder), and the assessment was
performed during maintenance ECT. No long-term studies of ver-
bal fluency are found in the literature, and other studies conducted
with adolescent samples with severe mood disorders have found no
significant differences in attention at long term follow-up (Cohen
et al. 2000; Russell et al. 2003).
No significant changes were detected in other neuropsycholo-
gical variables at 2-year follow-up. These results support other
long-term studies that have found no cognitive differences at
follow-up (Cohen et al. 2000; Russell et al. 2003). When we ana-
lyzed the results with a repeated-measures method, no significant
interaction time· group was found. Thus, the treatment with ECT
in our sample had no influence on changes in neuropsychological
variables. To our knowledge, no studies in the literature have aimed
at analyzing differences in neuropsychological change in adoles-
cent samples with schizophrenia treated with ECT.
Finally, the comparison between the ECT and the NECT groups at
2-year follow-up showed no significant differences between groups
in any clinical or neuropsychological variable. Kutcher and
Robertson (1995) studied a sample of 22 young patients, aged be-
tween 13 and 19, in whom a bipolar disorder was diagnosed and
divided them into two groups: 16 who accepted ECT and 6 who
refused it and continued with pharmacological treatment. A signifi-
cant improvement of clinical symptoms was observed in the ECT
group. No long-term follow-up studies in children or adolescents in
whom schizophrenia was diagnosed and who were treated with ECT
have been conducted using the PANSS to assess clinical outcome.
Regarding the cognitive assessment, there are few studies that
assess neuropsychological functions in adolescent samples with
which to compare our results. Nevertheless, our study supports the
research of Cohen et al. (2000) with affective patients. Theirs was
the only long-term follow-up study conducted with a sample of
adolescent patients treated with ECT, and they found no differences
in neuropsychological variables between the ECT group and a
psychiatric comparison group.
One of the main limitations of our study is the small sample size,
but this is due to the fact that ECT is not a first-choice treatment and
is only administrated in specific cases (following the AACAP
guidelines). As a result, the study is not powered enough to show rare
Table 3. Pharmacological Treatment
in Electroconvulsive Therapy (ECT)
and No Electroconvulsive Therapy Groups
Patients First assessment Second assessment
ECT1 Clozapine 400mg/day
Risperidone 3mg/day
Lorazepam 3mg/day
Clozapine 275mg/day
ECT2 Clozapine 600mg/day
Risperidone 2mg/day
Clozapine 275mg/day
Ziprasidone 240mg/day
ECT3 Trfluoperazine
25mg/day
Long acting Risperidone
50mg/14 days
ECT4 Aripiprazole 15mg/day
Lorazepam 3mg/day
Without treatment
ECT5 Risperidone 4mg/day
Clonazepam 2.5mg/day
Without treatment
ECT6 Risperidone 2mg/day
Quetiapine 1,200mg/day
Clozapine 500mg/day
ECT7 Oxcarbazepine
600mg/day
Lithium carbonate
1,600mg/day
Quetiapine
1,100mg/day
Clozapine 425mg/day
Rsiperidone 1mg/day
Lithium Carbonate
100mg/day
Valproic Acid
1,000mg/day
Diazepam 5mg/day
ECT8 Lithium Carbonate
1,000mg/day
Olanzapine 20mg/day
Clozapine 300mg/day
Lithium Carbonate
1,200mg/day
ECT9 Quetiapine 100mg/day Quetiapine 500mg/day
Valproic Acid 800mg/day
No-ECT1 Risperidone 6mg/day Risperidone 4mg/day
Propranolol 30mg/day
No-ECT2 Risperidone 3mg/day
Diazepam 5mg/day
Biperiden 4mg/day
Risperidone 1mg/day
Diazepam 10mg/day
No-ECT3 Risperidone 3mg/day
Propranolol 30mg/day
Lorazepam 1mg/day
Sertraline 150mg/day
Quetiapine 300mg/day
Valproic Acid 1,000
mg/day
No-ECT4 Quetiapine 400mg/day
Sertraline 100mg/day
Quetiapine 1,000mg/day
Sertraline 100mg/day
No-ECT5 Risperidone 4mg/day
Sertraline 100mg/day
Long Acting Risperidone
37.5mg/14 days
Risperidone 3mg/day
No-ECT6 Risperidone 4mg/day Risperidone 3mg/day
No-ECT7 Risperidone 5mg/day
Biperiden 1mg/day
Risperidone 4mg/day
No-ECT8 Risperidone 2mg/day
Lorazepam 2mg/day
Without treatment
No-ECT9 Risperidone 6mg/day Olanzapine 20mg/day
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incidence events such as those due to secondary effects. Another
limitation was that the cognitive assessment was not conducted in a
blind fashion, and biographic memory had not been assessed.
Among the strengths of the study, it should be noted that this
research has been conducted with two homogeneous samples of
adolescents in whom schizophrenia has been diagnosed and mat-
ched by age, socio-economic status, and PANSS total score to
avoid the influence of severity of clinical symptoms on the neu-
ropsychological assessment. Moreover, all subjects included in the
analysis had a long-term follow-up of clinical and cognitive vari-
ables that allowed us to assess the long-term influence of ECT on
cognitive functions. Indeed, this is the first study to investigate the
long-term influence of ECT treatment in a sample of children and
adolescents with schizophrenia.
Future research is needed to investigate the long-term cognitive
effects of ECT in adolescent patients in whom schizophrenia
spectrum disorders have been diagnosed.
Clinical Significance
The current study shows no significant differences in changes over
time in any clinical or neuropsychological variable between an ECT
group and a no-ECT group at follow-up. ECT did not seem to have
any negative influence on clinical or neuropsychological variables in
our sample at 2-year follow-up. Thus, ECT treatment should be taken
into serious consideration as a possible treatment in adolescents in
whom schizophrenia spectrum disorder is diagnosed, where patients
have not responded to at least two adequate pharmacotherapeutic
trials. More research is needed to increase knowledge about the long-
term effects of ECT on cognition in adolescent subjects.
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Table 4. Changes in Clinical and Neuropsychological Variables Between First and Second Assessment
in Electroconvulsive Therapy and No Electroconvulsive Therapy Groups
Time Time· group
Fa p-Value Fa p-Value
Clinical variables
PANSS positive 80.791 < 0.001 0.997 0.333
PANSS negative 0.711 0.412 0.415 0.528
PANSS general 30.263 < 0.001 0.716 0.410
PANSS total 24.671 < 0.001 0.110 0.745
CGI 110.278 < 0.001 0.405 0.533
Cognitive variables
Working memory
WAIS III digits backward 0.180 0.677 0.000 1.000
WAIS III letter and number 2.129 0.164 0.133 0.720
Attention
WAIS III digits forward 11.688 0.004 1.299 0.271
Time to complete TMT-A 3.996 0.063 0.184 0.673
Verbal memory
TAVEC total learning 4.068 0.062 0.008 0.930
TAVEC short-term free recall 2.301 0.150 0.017 0.899
TAVEC long-term free recall 1.369 0.260 0.004 0.952
Executive functions
Number of errors from TMT-B 3.004 0.107 0.651 0.434
Number of words on the FAS 2.938 0.110 0.180 0.679
Number of words on the semantic
category of FAS
9.229 0.010 0.012 0.914
Stroop interference score 2.365 0.148 0.776 0.394
WCST number of errors 1.267 0.281 1.742 0.210
WCST number of perseverative errors 4.659 0.050b 4.659 0.050b
WCST number of correct responses 0.70 0.796 0.129 0.726
WCST number of categories 0.059 0.812 0.059 0.812
Significant values marked in bold.
aMANOVA.
bRepeated measures analysis.
ECT-1= electroconvulsive therapy group at baseline; NECT-1= no electroconvulsive therapy group at baseline; ECT-2= electroconvulsive therapy
group at 2-year follow-up; NECT-2= no electroconvulsive therapy group at 2-year follow-up; PANSS= Positive and Negative Syndrome Scale;
CGI=Clinical Global Impressions-Improvement Scale; WAIS-III=Wechsler Adult Intelligence Scale Third Edition; TMT-A=Trail Making Test part A;
TAVEC=Complutense Verbal Learning Test; TMT-B=Trail Making Test part B; FAS= verbal fluency task; Stroop= Stroop color-word test;
WCST=Wisconsin Card Sorting Test; IQ= Intelligence Quotient.
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